LMATLEMAITRE VASCULAR INC

Nasdaq lemaitre.com


$ 76.05 $ 0.13 (0.17 %)    

Friday, 10-May-2024 15:59:55 EDT
QQQ $ 441.71 $ 1.04 (0.24 %)
DIA $ 395.04 $ 1.18 (0.3 %)
SPY $ 520.76 $ 0.67 (0.13 %)
TLT $ 90.14 $ -0.51 (-0.56 %)
GLD $ 218.73 $ 1.76 (0.81 %)
$ 76.13
$ 75.64
$ 0.00 x 0
$ 0.00 x 0
$ 75.35 - $ 76.16
$ 44.04 - $ 76.24
86,101
na
1.72B
$ 0.78
$ 50.61
TBD
na
na ($ 0.01)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-10-2024 03-31-2024 10-Q
2 02-29-2024 12-31-2023 10-K
3 11-07-2023 09-30-2023 10-Q
4 08-08-2023 06-30-2023 10-Q
5 05-09-2023 03-31-2023 10-Q
6 03-01-2023 12-31-2022 10-K
7 11-08-2022 09-30-2022 10-Q
8 08-05-2022 06-30-2022 10-Q
9 05-10-2022 03-31-2022 10-Q
10 02-28-2022 12-31-2021 10-K
11 11-04-2021 09-30-2021 10-Q
12 08-05-2021 06-30-2021 10-Q
13 05-10-2021 03-31-2021 10-Q
14 03-12-2021 12-31-2020 10-K
15 11-06-2020 09-30-2020 10-Q
16 08-06-2020 06-30-2020 10-Q
17 05-08-2020 03-31-2020 10-Q
18 03-12-2020 12-31-2019 10-K
19 11-08-2019 09-30-2019 10-Q
20 08-06-2019 06-30-2019 10-Q
21 05-06-2019 03-31-2019 10-Q
22 03-11-2019 12-31-2018 10-K
23 11-02-2018 09-30-2018 10-Q
24 08-06-2018 06-30-2018 10-Q
25 05-04-2018 03-31-2018 10-Q
26 03-09-2018 12-31-2017 10-K
27 11-03-2017 09-30-2017 10-Q
28 08-03-2017 06-30-2017 10-Q
29 05-04-2017 03-31-2017 10-Q
30 03-09-2017 12-31-2016 10-K
31 11-04-2016 09-30-2016 10-Q
32 08-05-2016 06-30-2016 10-Q
33 05-06-2016 03-31-2016 10-Q
34 03-10-2016 12-31-2015 10-K
35 11-06-2015 09-30-2015 10-Q
36 08-06-2015 06-30-2015 10-Q
37 05-07-2015 03-31-2015 10-Q
38 03-18-2015 12-31-2014 10-K
39 11-06-2014 09-30-2014 10-Q
40 08-07-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 barrington-research-maintains-outperform-on-lemaitre-vascular-raises-price-target-to-79

Barrington Research analyst Michael Petusky maintains LeMaitre Vascular (NASDAQ:LMAT) with a Outperform and raises the price...

 jmp-securities-maintains-market-outperform-on-lemaitre-vascular-raises-price-target-to-77

JMP Securities analyst Daniel Stauder maintains LeMaitre Vascular (NASDAQ:LMAT) with a Market Outperform and raises the pric...

 lemaitre-vascular-q1-2024-gaap-eps-044-beats-038-estimate-sales-53478m-beat-51506m-estimate

LeMaitre Vascular (NASDAQ:LMAT) reported quarterly earnings of $0.44 per share which beat the analyst consensus estimate of $0....

 stifel-upgrades-lemaitre-vascular-to-buy-raises-price-target-to-75

Stifel analyst Rick Wise upgrades LeMaitre Vascular (NASDAQ:LMAT) from Hold to Buy and raises the price target from $59 to $75.

 barrington-research-maintains-outperform-on-lemaitre-vascular-raises-price-target-to-69

Barrington Research analyst Michael Petusky maintains LeMaitre Vascular (NASDAQ:LMAT) with a Outperform and raises the price...

 lemaitre-vascular-q4-2023-gaap-eps-038-beats-036-estimate-sales-4888m-miss-4902m-estimate

LeMaitre Vascular (NASDAQ:LMAT) reported quarterly earnings of $0.38 per share which beat the analyst consensus estimate of $0....

 earnings-scheduled-for-february-27-2024

Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on rev...

 keybanc-initiates-coverage-on-lemaitre-vascular-with-sector-weight-rating

Keybanc analyst Brett Fishbin initiates coverage on LeMaitre Vascular (NASDAQ:LMAT) with a Sector Weight rating.

 lemaitre-vascular-sees-q4-eps-034-038-vs-034-est-revenue-48m-50m-vs-5019m-est-fy23-eps-132-136-vs-128-est-revenue-1926m-1946m-vs-19501m-est

Business OutlookQ4 2023 GuidanceFull Year 2023 Guidance Sales$48.0mm - $50.0mm(Mid: $49.0mm, +20%, +16% Org.)$192.6mm - $194.6m...

 lemaitre-vascular-q3-eps-033-beats-030-estimate-sales-4741m-miss-4759m-estimate

LeMaitre Vascular (NASDAQ:LMAT) reported quarterly earnings of $0.33 per share which beat the analyst consensus estimate of $0....

 earnings-scheduled-for-november-1-2023

Companies Reporting Before The Bell • GSK (NYSE:GSK) is expected to report quarterly earnings at $1.07 per share on revenue of...

 jmp-securities-initiates-coverage-on-lemaitre-vascular-with-market-outperform-rating-announces-price-target-of-60

JMP Securities analyst Daniel Stauder initiates coverage on LeMaitre Vascular (NASDAQ:LMAT) with a Market Outperform rating ...

 why-lemaitre-vascular-is-a-market-leader-in-core-segments-oppenheimer-initiates-with-outperform-rating

Oppenheimer has initiated coverage on LeMaitre Vascular Inc (NASDAQ: LMAT) with an Outperform rating and a 

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION